ChromaCode
Carol Gallagher is a Partner at NEA, joining in October, 2014. Carol is a proven entrepreneur, operator and more recently investor with nearly 30 years of experience in commercial, drug development and business development roles. Prior to joining NEA she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards. From 2008-2011, Carol was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG. Prior to Calistoga she served in various leadership roles at both large pharma and small biotech. In addition to serving as a director at Chromacode, she serves as Chairman of the Board at Millendo Therapeutics, lead director at Atara Bio, and as a director at Metacrine, PIONYR Immunotherapeutics, XOC, and Qpex.
This person is not in the org chart
This person is not in any offices
ChromaCode
ChromaCode is a molecular diagnostics company with a bioinformatics focus and pedigree from Illumina, Google[x], Luminex, and Caltech. They leverage patented mathematical methods and algorithmic enhancements to enrich signal processing from the most popular life science instrumentation. They use this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost.